Elanco Animal Health (NYSE:ELAN) Issues FY 2026 Earnings Guidance

Elanco Animal Health (NYSE:ELAN) updated its FY 2026 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 1.100-1.160 for the period, compared to the consensus EPS estimate of 1.070. The company issued revenue guidance of $5.1 billion-$5.1 billion, compared to the consensus revenue estimate of $5.1 billion. Elanco Animal Health also updated its Q3 2026 guidance to 0.190-0.220 EPS.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on ELAN. Piper Sandler reaffirmed an “overweight” rating on shares of Elanco Animal Health in a research report on Monday, June 29th. Citigroup increased their target price on shares of Elanco Animal Health from $30.00 to $31.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Weiss Ratings upgraded shares of Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday. TD Cowen increased their price objective on Elanco Animal Health from $31.00 to $32.00 and gave the company a “buy” rating in a report on Thursday, June 18th. Finally, Morgan Stanley raised their price objective on Elanco Animal Health from $23.00 to $26.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 22nd. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $28.73.

Elanco Animal Health Trading Down 0.6%

Shares of Elanco Animal Health stock opened at $25.56 on Wednesday. The firm’s 50 day simple moving average is $24.68 and its two-hundred day simple moving average is $24.09. The firm has a market capitalization of $12.77 billion, a price-to-earnings ratio of -51.12, a PEG ratio of 1.68 and a beta of 1.67. Elanco Animal Health has a 12-month low of $13.76 and a 12-month high of $27.72. The company has a current ratio of 2.16, a quick ratio of 1.12 and a debt-to-equity ratio of 0.60.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $0.34 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.07. The firm had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.31 billion. Elanco Animal Health had a negative net margin of 4.95% and a positive return on equity of 7.42%. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. Analysts predict that Elanco Animal Health will post 1.11 EPS for the current year.

Insider Transactions at Elanco Animal Health

In other news, insider Rajeev A. Modi bought 4,911 shares of the firm’s stock in a transaction that occurred on Friday, May 15th. The stock was purchased at an average price of $20.35 per share, with a total value of $99,938.85. Following the completion of the acquisition, the insider directly owned 160,812 shares of the company’s stock, valued at $3,272,524.20. This trade represents a 3.15% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Jeffrey N. Simmons purchased 4,971 shares of Elanco Animal Health stock in a transaction on Friday, May 15th. The shares were acquired at an average cost of $20.09 per share, with a total value of $99,867.39. Following the completion of the transaction, the chief executive officer directly owned 171,971 shares in the company, valued at $3,454,897.39. The trade was a 2.98% increase in their position. The SEC filing for this purchase provides additional information. 1.14% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Elanco Animal Health

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Guggenheim Capital LLC purchased a new stake in shares of Elanco Animal Health in the fourth quarter worth about $525,000. Bridgewater Associates LP purchased a new position in Elanco Animal Health during the fourth quarter valued at approximately $501,000. Cresset Asset Management LLC lifted its holdings in Elanco Animal Health by 89.8% in the third quarter. Cresset Asset Management LLC now owns 21,525 shares of the company’s stock valued at $434,000 after acquiring an additional 10,187 shares during the period. Vontobel Holding Ltd. acquired a new position in Elanco Animal Health in the fourth quarter valued at approximately $430,000. Finally, Meeder Advisory Services Inc. boosted its position in Elanco Animal Health by 4.8% in the 4th quarter. Meeder Advisory Services Inc. now owns 11,235 shares of the company’s stock worth $254,000 after purchasing an additional 510 shares in the last quarter. 97.48% of the stock is owned by institutional investors and hedge funds.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.